Home LiteratureArticle Details
PMID: 12070284 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.

The Journal of experimental medicine ·Vol. 195 ·No. 12 ·2002-06-17 ·Pages 1565-73

Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL, Seder RA

Abstract

CpG oligodeoxynucleotides (ODN) have potent effects on innate and adaptive cellular immune responses. In this report, the ability of CpG ODN to confer long-term immunity and protection when used as a vaccine adjuvant with a clinical grade of leishmanial antigen, autoclaved Leishmania major (ALM), or a recombinant leishmanial protein was studied. In two different mouse models of L. major infection, vaccination with ALM plus CpG ODN was able to control infection and markedly reduce lesion development in susceptible BALB/c and resistant C57BL/6 (B6) mice, respectively, up to 12 wk after immunization. Moreover, B6 mice immunized with ALM plus CpG ODNs were still protected against infectious challenge even 6 mo after vaccination. In terms of immune correlates of protection, ALM plus CpG ODN-vaccinated mice displayed L. major-specific T helper cell 1 and CD8+ responses. In addition, complete protection was markedly abrogated in mice depleted of CD8+ T cells at the time of vaccination. Similarly, mice vaccinated with a recombinant leishmanial protein plus CpG ODN also had long-term protection that was dependent on CD8+ T cells in vivo. Together, these data demonstrate that CpG ODN, when used as a vaccine adjuvant with either a recombinant protein or heat-killed leishmanial antigen, can induce long-term protection against an intracellular infection in a CD8-dependent manner.

MeSH Terms
Animals Antigens, Protozoan/administration & dosage Base Sequence CD4-Positive T-Lymphocytes/immunology CD8-Positive T-Lymphocytes/immunology CpG Islands Female Immunologic Memory Interferon-gamma/biosynthesis Leishmania major/immunology Leishmaniasis/prevention & control Lymphocyte Depletion Mice Mice, Inbred BALB C Oligodeoxyribonucleotides/administration & dosage Protozoan Proteins/administration & dosage Protozoan Vaccines/administration & dosage Recombinant Proteins/administration & dosage
Chemicals
Antigens, Protozoan Oligodeoxyribonucleotides Protozoan Proteins Protozoan Vaccines Recombinant Proteins Interferon-gamma
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Rhee Elizabeth G
Cellular Immunology Section, Vaccine Research Center, Bethesda, MD 20892, USA.
Mendez Susana
Shah Javeed A
Wu Chang-you
Kirman Joanna R
Turon Tara N
Davey Dylan F
Davis Heather
Klinman Dennis M
Coler Rhea N
Sacks David L
Seder Robert A
References (36)
36 references, click to expand
  1. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
    J Immunol. 1995 May 15;154(10):5320-30 PMID: 7730635
  2. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
    Science. 1994 Jan 14;263(5144):235-7 PMID: 7904381
  3. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization.
    Science. 1996 Jul 19;273(5273):352-4 PMID: 8662521
  4. Resistance to Leishmania major induced by tolerance to a single antigen.
    Science. 1996 Oct 18;274(5286):421-3 PMID: 8832890
  5. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
    J Immunol. 1996 Dec 1;157(11):5034-41 PMID: 8943412
  6. Contribution of CpG motifs to the immunogenicity of DNA vaccines.
    J Immunol. 1997 Apr 15;158(8):3635-9 PMID: 9103425
  7. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice.
    Immunity. 1997 May;6(5):541-9 PMID: 9175832
  8. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.
    Nat Med. 1997 Aug;3(8):849-54 PMID: 9256274
  9. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    J Exp Med. 1997 Oct 6;186(7):1137-47 PMID: 9314562
  10. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
    J Exp Med. 1997 Nov 17;186(10):1623-31 PMID: 9362523
  11. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis.
    J Immunol. 1998 Apr 15;160(8):3627-30 PMID: 9558060
  12. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family.
    Infect Immun. 1998 Jul;66(7):3279-89 PMID: 9632596
  13. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
    Nat Med. 1998 Dec;4(12):1409-15 PMID: 9846579
  14. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms.
    Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6970-5 PMID: 10359823
  15. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
    Infect Immun. 1999 Aug;67(8):3719-26 PMID: 10417129
  16. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.
    Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9305-10 PMID: 10430938
  17. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses.
    J Immunol. 2000 Aug 1;165(3):1228-35 PMID: 10903720
  18. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.
    Lancet. 2000 Nov 4;356(9241):1565-9 PMID: 11075771
  19. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins.
    Eur J Immunol. 2000 Dec;30(12):3591-7 PMID: 11169401
  20. A Toll-like receptor recognizes bacterial DNA.
    Nature. 2000 Dec 7;408(6813):740-5 PMID: 11130078
  21. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers.
    Vaccine. 2001 Feb 28;19(15-16):2100-6 PMID: 11228382
  22. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    J Immunol. 2001 Apr 15;166(8):5122-8 PMID: 11290794
  23. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.
    Infect Immun. 2001 Jun;69(6):4103-8 PMID: 11349082
  24. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.
    J Immunol. 2001 Nov 1;167(9):4878-86 PMID: 11673492
  25. CpG oligodeoxynucleotides as vaccine adjuvants in primates.
    J Immunol. 2002 Feb 15;168(4):1659-63 PMID: 11823494
  26. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.
    J Immunol. 2002 Apr 15;168(8):3992-4000 PMID: 11937556
  27. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
    Infect Immun. 2002 Aug;70(8):4215-25 PMID: 12117930
  28. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.
    J Exp Med. 1990 Jan 1;171(1):115-27 PMID: 2104918
  29. Recombinant interleukin 12 cures mice infected with Leishmania major.
    J Exp Med. 1993 May 1;177(5):1505-9 PMID: 8097524
  30. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism.
    Nat Biotechnol. 2000 May;18(5):509-14 PMID: 10802617
  31. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    J Immunol. 2000 Jul 1;165(1):539-47 PMID: 10861094
  32. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.
    J Immunol. 2000 Jul 15;165(2):915-24 PMID: 10878366
  33. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity.
    J Immunol. 2000 Jul 15;165(2):969-77 PMID: 10878373
  34. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge.
    Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8427-32 PMID: 10890924
  35. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.
    J Exp Med. 1993 Jun 1;177(6):1797-802 PMID: 8098733
  36. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83 PMID: 8610135
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
2002-06-17
Pages
1565-73
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2193566
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]